18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis

• DOI: 10.1136/ijgc-2022-igcs.62
• Publication Date: 2022-12-25T16:03:36Z
• Authors: Kathleen Moore; David O’Malley; Ignace Vergote; Lainie Martin; Antonio Gonzalez-...; Jiuzhou Wang; Michael Method; Michael Birrer
• Keywords: Carboplatin; Tolerability

<h3>Objectives</h3> Mirvetuximab soravtansine (MIRV) is a first-in-class ADC comprising folate receptor-α (FRα)-binding antibody, cleavable linker, and maytansinoid DM4 payload. As part of the phase 1b/2 trial (NCT02606305), efficacy safety MIRV carboplatin (carbo) were evaluated in patients with recurrent FRα-positive platinum sensitive ovarian cancer (PSOC) measured by immunohistochemistry (PS2+ ≥25%; table 1). <h3>Methods</h3> Eighteen received carbo intravenously on Day 1 3-week cycle using standard 3 + design, starting dose 5 mg/kg adjusted ideal body weight (AIBW) AUC4. FRα positivity ≥25%) was required. Primary endpoint confirmed ORR RECIST v1.1. <h3>Results</h3> Ten 6 AIBW AUC5. Anti-tumor activity observed all escalation cohorts varying levels expression. Patients receiving AUC5 had an 89%, mDOR 12.1, mPFS 16.5 months. medium/high FRα-expressing tumors 80%, 24.2, 15.0 months across (table 2). The most frequent treatment-emergent adverse events (all, grade 3+) included nausea (72%, 0%), diarrhea (67%, 6%), blurred vision thrombocytopenia (61%, 17%), fatigue 11%), neutropenia (56%, 28%). <h3>Conclusions</h3> demonstrated anti-tumor PSOC. selected as 2 dose. This combination being one planned two ongoing (NCT04606914 NCT04274426) studies.